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Structure of the UDP-Glucosyltransferase GtfB
That Modifies the Heptapeptide Aglycone in the
Biosynthesis of Vancomycin Group Antibiotics
lin-resistant Staphylococcus aureus (MRSA), with van-
comycin and teicoplanin approved for human use and
such analogs as avoparcin of previous widespread use
as an animal growth promotant [1]. Given the role of
vancomycin, both as a front-line drug and as a drug of
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2 Department of Biological Chemistry last resort in the treatment of life-threatening infections
by Gram-positive pathogens, there has been much con-and Molecular Pharmacology
Harvard Medical School cern over the explosive rise in clinically significant resis-
tance in the opportunistic pathogenic enterococci [2].Boston, Massachusetts 02115
Vancomycin-resistant enterococci (VRE) have become
widespread pathogens in nosocomial infections and
carry high morbidity and mortality, especially in im-Summary
muno-compromised patient populations. This concern
has been translated into a resurgence of interest in van-Background: Members of the vancomycin group of gly-
copeptide antibiotics have an oxidatively crosslinked comycin alternatives and analogs that will work against
VRE [3–5].heptapeptide scaffold decorated at the hydroxyl groups
of 4-OH-Phegly4 or -OH-Tyr6 with mono- (residue 6) or Due to the structural complexity of the vancomycin
group of antibiotics (Figure 1), especially the oxidativedisaccharides (residue 4). The disaccharide in vancomy-
cin itself is L-vancosamine-1,2-glucose, and in chloroer- crosslinks between the aryl rings of residues 2, 4, and
6 and 5 and 7, total synthesis of vancomycin and itsemomycin it is L-4-epi-vancosamine-1,2-glucose. The
sugars and their substituents play an important role in congeners has been difficult and is likely to remain im-
practical. This inaccessibility has prompted closer ex-efficacy, particularly against vancomycin-resistant patho-
genic enterococci. amination of the biosynthetic logic for assembly of this
class of antibiotics. It has been known for some years
that the heptapeptide core (D-D-L-D-D-L-L) is likelyResults: The glucosyltransferase, GtfB, that transfers
the glucose residue from UDP-glucose to the 4-OH- assembled by a nonribosomal peptide synthetase
(NRPS), and such genes are included in the sequence ofPhegly4 residue of the vancomycin aglycone, initiating
the glycosylation pathway in chloroeremomycin matura- a cluster of 39 orfs in the chloroeremomycin-producing
Amycolaptosis orientalis [6]. Chloroeremomycin differstion, has been crystallized, and its structure has been
determined by X-ray analysis at 1.8 A˚ resolution. The from vancomycin only in the number and placement of
4-epi-vancosamine sugars in place of the vancosamineenzyme has a two-domain structure, with a deep inter-
domain cleft identified as the likely site of UDP-glucose sugar found in vancomycin (Figure 1).
There are three discernable phases to the assemblybinding. A hydrophobic patch on the surface of the
N-terminal domain is proposed to be the binding site of this class of glycopeptide antibiotics. The first phase
involves the NRPS assembly line that activates theof the aglycone substrate. Mutagenesis has revealed
Asp332 as the best candidate for the general base in seven amino acids, then elongates and releases the
acyclic, flexible heptapeptide chain. In the secondthe glucosyltransfer reaction.
phase, the oxidative crosslinking of the five aryl side
chains of residues 2, 4, 5, 6, and 7 creates the rigid cup-Conclusions: The structure of GtfB places it in a grow-
ing group of glycosyltransferases, including Escherichia shaped architecture of the aglycone core with aryl ether
links between -OH-Tyr2-OH-Phegly4 and OH-Phegly4-coli MurG and a -glucosyltransferase from T4 phage,
which together form a subclass of the glycosyltransfer- -OH-Tyr6 and a direct C-C link between OH-Phegly5-
(OH)2Phegly7. The third phase involves the post-NRPSase superfamily and give insights into the recognition
of the NDP-sugar and aglycone cosubstrates. A single glycosylation of the oxidized heptapeptide scaffold, first
at the phenolic hydroxyl of 4-OH-Phegly4 (Figure 1) andmajor interdomain linker between the N- and C- terminal
domains suggests that reprogramming of sugar transfer then at various other sites, e.g., residue 6 in chloroere-
momycin and residues 6 and 7 in teicoplanin, to createor aglycone recognition in the antibiotic glycosyltrans-
ferases, including the glycopeptide and also the macro- the mature glycopeptide. The glycosylations affect
aqueous solubility, offer sites for lipid attachment andlide antibiotics, will be facilitated by this structural infor-
mation. membrane association, and provide selectivity against
VRE [7–9].
In the vancomycin family, the first sugar attached toIntroduction
the aglycone is a D-glucose that is transferred to the
phenolic hydroxyl of OH-Phegly4 by a specific glycosyl-The glycopeptide antibiotics of the vancomycin family
are effective agents in the treatment of Gram-positive transferase (GTF). Then, a second sugar, L-vancosamine,
bacterial infections, including those caused by methicil-
Key words: glycosylation; antibiotic biosynthesis; vancomycin;
X-ray crystal structure; family 1 glycosyltransferases, UDP-glucose;3 Correspondence: garavito@msu.edu (R.M.G.), christopher_walsh@
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Figure 1. Structure and Glycosylation Pattern of Vancomycin and Chloroeremomycin
The structures of two vancomycin group antibiotics are shown, with the crosslinked amino acids numbered. The sugars are labeled in each
structure, and for chloroeremomycin, the enzymes responsible for the glycosyl transfer are shown above the indicated sugar.
is added by a second GTF to create a vancosaminyl- and packs against the N-terminal domain, creating an
interface of18 A˚ in length that consists almost entirely1,2-glucosyl disaccharide chain. In the chloroeremo-
mycin biosynthetic cluster, there are three GTF genes of hydrophobic interactions. Otherwise, interdomain
contacts are relatively limited; only four hydrogen bondsin tandem, orfs 11, 12, and 13, corresponding to GtfA,
GtfB, and GtfC, respectively. GtfB transfers the glucose are observed between side chains of the C-terminal
domain and main chain atoms from N-terminal domainmoiety from a UDP-glucose donor to the vancomycin
aglycone acceptor. While the exact order of the two loops immediately following the N5 and N6 strands.
Three peptide segments in the GtfB crystal structureremaining glycosylations is unknown, GtfC is the pre-
sumed 4-epi-vancosaminyltransferase to create the have poor or no electron density, indicating conforma-
tional flexibility for these regions. One of these segmentsanalogous 4-epi-vancosaminyl-glucosyl disaccharide,
and GtfA transfers L-4-epi-vancosamine onto the (residues 246–248) corresponds to part of the glycine-
rich region on the C-terminal domain. Two additional-hydroxyl group of -OH-Tyr6 (Figure 1).
GTFs that decorate aglycone portions of antibiotics, longer disordered regions, including residues 54–63 and
140–148, occur on adjacent surfaces of the N-terminalwhether in the glycopeptide or the macrolide antibiotics,
such as erythromycin [10–12], are promising tools for domain. Figure 2c illustrates the abrupt end in electron
density observed at residue 139, which, interestingly,the generation of chemical diversity if they can be engi-
neered to accept either alternate aglycones or alternate follows a well-ordered sequence of four consecutive Pro
residues. These latter disordered regions overlap withNDP-sugar donor substrates. However, little is known
about the structure or determinants of recognition or hypervariable regions (residues 55–82 and 134–164),
which are seen in the amino acid sequence alignmentsselectivity [13]. In this work, we report the X-ray crystal
structure of the first glycosyltransferase that decorates of the closely related glycosyltransferases from organ-
isms producing vancomycin-class antibiotics (Figure 3).the crosslinked aglycone of the vancomycin family, the
glucosyltransferase GtfB from the chloroeremomycin It is also possible that a larger portion of the GtfB
N-terminal domain may be flexible in solution, as thebiosynthetic cluster.
long helix formed by residues 69–82, which immediately
follows one of these disordered segments, is stabilizedResults and Discussion
in the X-ray structure by crystal-packing interactions.
Overall Structure
The GtfB structure is comprised of two distinct N- and Structural Homology
The crystal structures of a number of other glycosyl-C-terminal halves, similar in size and topology and sepa-
rated by a deep cleft (Figure 2a). Both domains contain a transferases have recently been determined [14–21].
GtfB shares a conserved topology with two of thesesimilar core structure of parallel  sheets (N1–7, C1–6)
connected by  helices (Figure 2b); this motif is com- structures, despite little or no amino acid sequence simi-
larity (Figure 4). The more similar of these, at 20%monly referred to as a Rossmann fold and is generally
associated with dinucleotide binding. Moreover, the amino acid sequence identity, is the UDP-N-acetylglu-
cosaminyltransferase MurG from E. coli, which transfersC-terminal domain includes a Gly fingerprint sequence
immediately following the 1 strand (G244-X-G246-XX-G249), N-acetyl glucosamine to the peptidoglycan precursor
during the biosynthesis of the cell wall [15]. The  sheetwhich is characteristic of the classical Rossmann fold
and is an important element in dinucleotide binding. At core structures of the two enzymes are superimposable
with an overall rmsd on C atoms (186 residues) of 1.9 A˚,the corresponding position on the N-terminal domain,
a G9-XX-G12 sequence may represent a vestigial Gly-rich while the N- and C-terminal domains superimpose in-
dependently with rmsd values of 1.5 A˚ and 0.6 A˚, re-sequence (Figure 2a). The two halves of the protein are
connected by an extended interdomain linker peptide. A spectively. GtfB is also structurally homologous to the
-glucosyltransferase of T4 phage (-GT), which gluco-long helical tail also extends from the C-terminal domain
Structure of the UDP-Glucosyltransferase GtfB
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Figure 2. Views of the GtfB Structure
(a) A backbone representation of GtfB along
with the position of the bound sulfate ion
(yellow).
(b) A ribbon representation of GtfB highlights
the  strands of the Rossmann fold in each
domain as well as the residues bordering the
disordered regions.
(c) The abrupt end in electron density at
Pro139 is shown as it enters the disordered
region of the second hypervariable region,
following the well-resolved four proline
stretch, 136–139.
Figures 2, 4, and 5 were generated using
SETOR [38].
sylates hydroxymethyl cytosine of DNA [14, 22]. Individ- be grouped into a single superfamily despite a lack of
noticeable amino acid sequence similarity. Unligil andually, the conserved  sheet structures of the N- and
C-terminal domains of GtfB and -GT superimpose with Rini [24] recently noted that five other previously de-
termined glycosyltransferase structures can also bean rmsd of 2.0 A˚ and 1.5 A˚, respectively. However, when
the entire structures of GtfB and -GT are superim- grouped into two homologous superfamilies and pre-
dicted that many other glycosyltransferases originallyposed, the overall rmsd is 3.6 A˚, reflecting a large differ-
ence in the relative disposition of the two domains in categorized into separate families, based on sequence
similarity, might also be related. The structure of GtfBthe two enzymes. Ha et al. [15] have also discussed the
analogous structural relationship between -GT and MurG. further supports this prediction.
The broader structural/functional class of family 1/GtfB was originally classified by Campbell et al. [23]
within family 1 of 26 families of NDP-sugar glycosyltrans- family 28 NDP-sugar glycosyltransferases seems to
have evolved to transfer a sugar moiety from many dif-ferases, based on amino acid sequence similarity and
reaction stereochemistry. This classification system, ferent NDP-sugar donors to an enormous variety of ac-
ceptor substrates. For example, family 1 glycosyltrans-which has expanded as new families are described (an
updated server is found at URL http://afmb.cnrs-mrs.fr/ ferases also include an important class of vertebrate
UDP-glucuronosyltransferases that are instrumental inpedro/CAZY/db.html), now includes 51 subfamiles.
MurG has been classified in family 28, while, in contrast, the clearance of potentially toxic fat-soluble metabolites
and xenobiotics. Thus, it is probable that these enzymes-GT could not be classified into any one of the families
due to a lack of sequence similarity. The structural ho- have a three-dimensional structure very similar to that
of GtfB as well. A more distant evolutionary relationshipmology between GtfB, MurG, and -GT clearly demon-
strates that families 1 and 28, as well as -GT, can was found between -GT and phosphorylase [25, 26],
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Figure 3. Sequence Alignment of Eight GTFs
Involved in HPC Glycosylation
The aligned sequences of cGtfB (chloroere-
momycin gtfB, CAA11775.1), bGtfB (balhi-
mycin gtfB, CAA76552.1), vGtfE (vancomycin
gtfE, AAB49299.1), cGtfC (chloroeremomycin
gtfC, CAA11776.1), bGtfC (balhimycin gtfC,
CAA76553.1), vGtfD (vancomycin gtfD,
AAB49298.1), cGtfA (chloroeremomycin gtfA,
CAA11774.1), and bGtfA (balhimycin gtfA,
CAA76551.1) show the close relationship be-
tween these enzymes. Elements of second-
ary structure are indicated, and locations of
the interdomain linker peptide (blue), the heli-
cal tail (pink), glycine-rich regions (yellow),
and hypervariable regions (green) are high-
lighted.
suggesting that family 1 NDP-sugar glycosyltransfer- cessful. Even when crystals of the enzyme are grown
ases may be part of a larger structural, although not at UDP-glucose concentrations up to 25 mM (Km  1.3
necessarily functional, superfamily. mM), no electron density is observed to indicate the
The possibility of a common evolutionary origin for presence of bound substrate, and the refined protein
GtfB, MurG, and -GT is an intriguing question, despite structure is virtually identical (0.27 A˚ rmsd on main chain
the low levels of amino acid sequence similarity between atoms) to that of GtfB crystallized in the absence of a
these enzymes. Such considerations can also be ex- substrate. As the homologous T4 phage -GT has been
tended to the N- and C-terminal domains, which also reported to cleave UDP-glucose [22], one explanation
share marked topological similarity (rmsd of 1.65 A˚ for for the lack of binding is that, in GtfB, the substrate is
62 C atom pairs in GtfB). The 23% sequence identity similarly hydrolyzed and then released; however, only
between the two GtfB domains is rather low, but it is very low rates of UDP-glucose hydrolysis have been
comparable to the 22% sequence identity observed be- measured in solution (H.C.L. and C.T.W., unpublished
tween the N-terminal domains of GtfB and MurG. This data). A second possibility is an ordered-sequential
observation suggests that the enzyme may have evolved binding mechanism for substrates in GtfB, in which prior
by a gene duplication/fusion event. binding of the aglycone acceptor is required to induce
a conformational change that then creates a functional
UDP-glucose binding subsite in the enzyme. An or-UDP-Glucose Substrate Binding
dered-sequential binding mechanism has been ob-All attempts to observe the GtfB/UDP-glucose binary
complex by X-ray crystallography have been unsuc- served recently for a macrolide glycosyltransferase
Structure of the UDP-Glucosyltransferase GtfB
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Figure 4. Stereo View Showing Ribbon Dia-
grams of Homologous GtfB, MurG, and T4
-GT Structures
A high degree of conservation of the  sheets
(highlighted in blue) is clearly visible. In the
T4 -GT structure, the bound UDP is shown
in red.
from Streptomyces antibioticus [13] in which binding of specific side chain interactions that may be involved in
substrate binding by GtfB. Only a G-S sequence oc-UDP-glucose was dependent on prior binding of the
lankamycin acceptor substrate. curring in the glycine-rich sequence on the C-terminal
domain is common to both enzymes. In the -GT com-The approximate location of the UDP-glucose binding
site may be inferred from the X-ray crystal structure of plex, the side chain of Ser189 forms a hydrogen bond
with the pyrophosphate of bound UDP and is part ofthe binary complex of T4 phage -GT and UDP [14]. In
this structure, UDP was bound against the surface of a flexible loop that becomes ordered upon substrate
binding [14]. As noted above, structurally homologousthe C-terminal domain within the interdomain cleft (Fig-
ure 5a). The assumption that UDP-glucose binds to a Ser247 is part of a short disordered loop in GtfB. Con-
served as either Ser or Thr in even distantly relatedcorresponding position in the GtfB cleft is supported by
some experimental evidence: in the crystal structure, a enzymes, it is probable that this side chain plays a similar
role in substrate binding by GtfB.sulfate anion binds to GtfB near the expected position
of the substrate pyrophosphate bridge (Figure 5b). How- One striking difference between the presumed UDP-
glucose binding sites in -GT and GtfB involves theever, since amino acids in this region differ greatly be-
tween the two enzymes, it is difficult to predict any stabilization of the pyrophosphate. In the -GT complex,
Structure
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Figure 5. Stereo Views of the C-Terminal Do-
mains of -GT and GtfB
(a) The UDP binding site and surrounding res-
idues in -GT [14], with bound UDP shown in
blue. Two of the three arginines that ligand
the pyrophosphate in -GT (Arg191 and
Arg269) are shown.
(b) The C-terminal domain of GtfB is shown
with the bound sulfate (yellow) sitting at the
N-terminal end of the C4 helix. The Asp332,
the best candidate for the general base, is
shown in red.
the pyrophosphate moiety of UDP is surrounded by the and N5 strands, form a shallow pocket 18 A˚ across.
positive charges of three Arg side chains on the surface At the center of the pocket lie the side chains of Leu102
of the C-terminal domain. Likewise, comparisons with and Leu103, surrounded on either side by a region of
the MurG crystal structure revealed an Arg side chain aromatic residues (Tyr122, Phe124, Tyr129, Tyr166,
in similar position, which was suggested to form an Phe186, and Tyr190) and a region of smaller hydropho-
analogous contact [15]. In contrast, no basic side chains bic amino acids (Cys8, Ala79, Ala104, and Ala105). The
are found in this region of the GtfB structure. Instead, two long hypervariable loops, flexible in the GtfB crystal
the pyrophosphate moiety is more likely stabilized pri- structure, are located on the same surface of the protein,
marily by the positive dipole of the C4 helix, as is seen in flanking the proposed acceptor binding pocket, sug-
more classical nucleotide binding enzymes. The sulfate gesting they might also play a role in substrate binding
anion bound in this position in the GtfB crystal structure or specificity. The same face of the N-terminal domain
may mimic binding of the UDP phosphate moieties. was also predicted to be the acceptor binding site for
Moreover, the turn preceding the C4 helix contains a both -GT and MurG [14, 15]. The three enzymes show
Gly-rich sequence, (HHGGAGT), which is one of few the least conservation of three-dimensional structure in
highly conserved segments among even some of the this region, consistent with the diversity of acceptor
more distantly related amino acid sequences (Figure 6). substrates upon which they act. For MurG, Ha et al.
Although disordered in the crystal structure, the side [15] proposed that the N-terminal domain was further
chain of Arg11 on the adjacent surface of the N-terminal modified to incorporate membrane binding by altering
domain may also be suitably positioned to interact with the surface just beyond the second hypervariable
the UDP pyrophosphate bridge. However, this possibil- domain.
ity contrasts with what is seen in the-GT/UDP complex, Figure 7b shows a model for the aglycone substrate,
in which binding interactions with UDP were contributed based on the known X-ray structure of the vancomycin
only by the C-terminal domain [14]. antibiotic [27], manually docked on the GtfB surface.
Using the constraint that the reactive hydroxyl of the
aglycone be oriented toward the presumed UDP-glu-Aglycone Acceptor Binding Site
cose binding cleft, the highly rigid acceptor substrateThe surface of the N-terminal domain adjacent to the
is easily positioned within the pocket, conforming well tointerdomain cleft contains a distinctive patch of aro-
the concave surface of the enzyme and making minimalmatic and hydrophobic side chains. We propose it to
steric clashes that may be alleviated by only minorbe the probable acceptor binding site (Figure 7a). These
residues, primarily located on the loops following N4 changes in side chain conformations.
Structure of the UDP-Glucosyltransferase GtfB
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Figure 6. A Sequence Alignment Between
More Distantly Related Glycosyltransferases
The region of the highly conserved Gly-rich
sequence HHGGAGT (blue box) as well as
the strictly conserved Pro323 and the highly
conserved Asp 332, the potential catalytic
base (asterisk), are highlighted. The se-
quences referred to are: cgtfB (chloroeremo-
mycin gtfB, CAA11775.1), bgtfB (balhimycin
gtfB, CAA76552.1), GtfD (vancomycin gtfD,
AAB49298.1), Mtgtf (putative gtf, Mycobacte-
rium tuberculosis, CAB01398.1), Mlgtf (puta-
tive gtf, Mycobacterium leprae, AAA17353.1),
Martf (rhamnosyltransferase rtfA, Mycobacterium avium, AAD20364.1), Atgtf (putative UDP-glucose:sterol glucosyltransferase, Arabidopsis
thaliana, AAD39269.1), EreC (erythromycin gtf eryCIII, Saccharopolyspora erythraea, CAA74710.1), OleG2 (gtf in oleandomycin biosynthesis,
Streptomyces antibioticus, CAA05642.1), dnrS (daunosaminyltransferase dnmS, Streptomyces peucetius, AAD15267.1), MurG (UDP-N-acetyl-
glucosaminyltransferase, Escherichia coli, P17443), eryBV (gtf in erythromycin biosynthesis, Saccharopolyspora erythraea, AAB84072.1), dnrH
(putative gtf in baumycin biosynthesis, Streptomyces peucetius, AAD04714.1), urdGT1a (gtf in urdamycin A biosynthesis, Streptomyces fradiae,
AAF00214.1), and Ugatf (human UDP-glucuronosyltransferase 2B-4 precursor, JN0619).
Among the closely related antibiotic pathway GTFs, engineering of altered substrate selectivity can be con-
ceived. However, the basic architecture of the enzymeresidues forming the hydrophobic pocket are fairly well
conserved (Figure 3). However, differences are more itself observed in this work reveals potential avenues
for the development of antibiotic diversity. The presencepronounced for GtfA, as would be expected for this
enzyme that is unique in transferring the sugar moiety of two virtually independent structural domains, each
having distinct acceptor and donor substrate bindingto the 6-position on the aglycone heptapeptide rather
than position 4 (Figure 1). The substitution of Leu102 functions, suggests that chimeric enzymes, consisting
of N- and C-terminal domains derived from related GTFsfor Asp or Glu in the GtfC and GtfD enzymes is also
consistent with this hypothesis, as the latter residues having differing acceptor and donor specificities, could
be constructed. The C-terminal helical tail, which packsprovide a more suitable surface for binding the glucosyl
moiety of the monosaccharide aglycone substrate dur- against the N-terminal domain surface, represents the
most significant interface between the two domains.ing formation of the disaccharide linkage (Figure 1).
The direct observation of GtfB complexes with the However, this interface occurs on the opposite surface
of the enzymes from both substrate binding sites. More-aglycone and UDP-glucose substrates by X-ray crystal-
lographic analysis, as well as site-directed mutagenesis over, residues of both the helical tail (Ala387, Ala390,
Ala391, Leu394, and Val398) and N-terminal domainstudies, will be necessary to understand the determi-
nants of substrate binding and specificity before the (Leu20, Val24, Leu27, Ala29, Ala96, Val98, Pro119, Phe121,
Figure 7. Molecular Surface Views of the
N-Terminal Domain With Proposed Acceptor
Binding Site
(a) The stereo view of the empty aglycone
site has the surface colored to highlight the
locations of Leu102 and Leu103 at the center
of the hydrophobic pocket (yellow), aromatic
side chains (magenta), disordered peptides
(green), and the interdomain linker peptide
(cyan).
(b) A close-up view of the aglycone site shows
the approximate position of bound UDP-glu-
cose as derived from superposition of the
conserved  sheet structure of the C-terminal
domain with that of the -GT binary complex
with UDP (see text). A model for the possible
position of the vancomycin aglycone bound
on the surface of the N-terminal domain is
also shown. The phenolic oxygen of the
4-OH-Phegly4 can be positioned near the C1
atom of the glucosyl ring, as would be re-
quired for hexose transfer.




Table 3. Statistics of CNS Structure RefinementTable 1. Steady-State Kinetic Parameters of GtfB Wild-Type and
Mutant Enzymes
Type I Type II
kcat (min1) Km, UDP-glucose (mM) Resolution (A˚) 30–1.8 30–2.3
Total atoms 3,094 2,905Wild-type GtfB 33  4 1.3  0.1
D13A 2.6  0.3 1.1  0.1 Amino acids 382 376
Waters 293 163H125A 43  3 0.45  0.04
D332A 0.13  0.03 3.3  0.8 Ions 2 Mg2, 1 SO42 2 Mg2
Reflections, working set 37,146 18,161
Test set 2,867 931
R factor (%) 21.1 20.9
Trp195, Thr215, and Trp218) that form these hydropho- Rfree (%) 23.1 24.1
bic packing interactions are highly conserved between B	 (A˚2) 21.1 21.2
Rmsdclosely related GTFs. Hence, the structural obstacles








Little is known about the catalytic mechanism of GtfB,
or family 1 glycosyltransferases as a whole. Mechanisms
proposed for other glycosyltransferase families [24] glycosyltransferases (Figure 6). The D332A mutant en-
zyme, when purified and assayed, exhibited a kcat thathave postulated that transfer is initiated by a general
base that abstracts a proton from the reactive acceptor was reduced 250-fold compared to the wild-type en-
zyme (0.13 min1 versus 33 min1, respectively), with nohydroxyl, followed by nucleophilic attack at the sugar
C1 carbon center. An inspection of the GtfB structure significant change in the Km for UDP-glucose (3.3 mM
versus 1.3 mM) (Table 1). This decrease is sufficientlyto identify candidates for the general base revealed that
the side chains of Asp13 and His125 are at suitable large to make D332 a credible candidate for part of the
catalytic apparatus in this family of glycosyltransfer-positions near the interface between the proposed do-
nor and acceptor binding sites and are within hydrogen ases. Although the modeled position of the bound agly-
cone substrate on the surface of the N-terminal domainbonding distance of one another. Of these, Asp13 is
conserved in all closely related GTFs (Figure 3). More- puts the accepting hydroxyl far from the Asp332 side
chain, transfer might be easily accommodated by aover, both residues correspond, topologically and spa-
tially, to candidate residues for the general base in conformational change in the enzyme upon substrate
binding. Among related enzymes, a closing of the -GT-GT, Glu22, and Asp100 [22]. Morera et al. [22] suggest
that Asp100 is the most likely candidate for the general interdomain cleft upon UDP-glucose binding was dem-
onstrated crystallographically [14], and conformationalbase in -GT. Based on these criteria, Asp13 and His125
were considered as candidates for the expected base changes upon acceptor binding have been suggested
for a S. antibioticus glycosyltransferase [13]. Hence, ain GtfB. However, mutational analysis has shown that
neither side chain is essential for catalysis by GtfB. The more valid picture of the GtfB active site may require
the structure of an abortive GtfB ternary complex tokcat of the D13A mutant is 2.6 min1, down about 10-fold
from wild-type GtfB, with no change in the Km for UDP- establish which residues are critical to the sugar-transfer
reaction.glucose (Table 1). GtfB-H125A shows no decrease in
catalytic rate, with a kcat of 43 min1, compared to a rate Many glycosyltransferases, including the family 1 en-
zymes such as MurG and -GT, are also assumed toof 33 min1 for wild-type GtfB. These results also raise
doubt about the choice of Asp100 as the general base require Mn2or other divalent cations for optimal activity
[24]. Interestingly, despite the overall structural andin -GT [22].
The only other residue identified in the GtfB crystal functional similarity with -GT and MurG, GtfB does not
share this mechanistic requirement. In fact, the rate ofstructure that appears to be in a reasonable position to
serve as a catalytic base is Asp332 on the adjacent catalysis by GtfB was found to decrease with increasing
concentrations of Mg2 and be unaffected by the pres-surface of the C-terminal domain (Figure 5b). Unlike
Asp13 and His125, this amino acid is also highly con- ence of EDTA (H.C.L. and C.T.W., unpublished data).
Although a high concentration of Mg2 cations in theserved among distantly related members of family 1
Table 2. Statistics of Data Collection and MIR Phasing
Data Set Resolution (A˚) Completeness (%) I/	 Rsym (%) Rmer (%) Number of Sites Phasing Powera
Native 1 2.8 99.6 28.2 6.5
Native 2 1.8 99.7 26.8 4.9
Type II native 2.3 96.6 21.0 6.8
Dichlorodiamine Pt (II) 2.8 99.3 20.5 7.8 15.0 4 1.17
Ethylmercurithiosalicylate 2.8 99.0 21.1 7.6 25.6 2 0.88
UO2(NO2)2 3.0 98.5 21.1 7.1 13.8 2 0.52
KAu(CN)2 3.2 98.2 20.6 8.0 30.0 2 0.48
a Phasing power  Fh	/E	, where Fh	 is the heavy atom scattering factor and E	 is the rms of the lack-of-closure.
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CGAAGGCATAGAAG). The 3 SOE fragments were amplified usingGtfB crystallization medium was essential for successful
the forward primer gtfB-D13A-3for (GGATCGCGCGGAGCTACCcrystal nucleation and growth, no cations are observed
GAACCGCTG) or gtfB-H125A-3for (CTATGCCTTCGCCTGTCCto be bound at or near the proposed substrate binding
GAGTTATG) and the reverse primer 3pET (GCTTTGTTAGCAGCCG
sites. Two well-resolved Mg2 cations are observed in GATC). Each of the two PCR-amplified DNA fragment products from
the crystal structure, easily recognizable as tetrahedral the first round were gel purified and used as the templates during
a second round of amplification with the forward primer 5pET andMg-water clusters; both mediate crystal packing inter-
the reverse primer 3pET to yield the final DNA products containingactions that are distant from the proposed active site.
the desired mutations. The spliced products were digested with
NdeI/XhoI and ligated into pET22b that was digested likewise. TheBiological Implications
ligations were transformed into DH5 cells to propagate the plas-
mids. After sequencing the inserts to verify the correct mutations,
The GtfB glucosyltransferase is the enzyme that initiates the plasmids were transformed into BL21(DE3), and the proteins
were overproduced and purified as described for GtfB.the glycosylation of the core of the vancomycin group
Assays with GtfB, GtfB-D13A, GtfB-H125A, and GtfB-D332A wereof glycopeptide antibiotics. GtfB adds a glucose moiety
performed as previously described for crude extracts of GtfB [29],from UDP-glucose to the attacking phenolic oxygen of
except purified enzymes, GtfB (50 nM), GtfB-D13A (50 nM), GtfB-the 4-OH-Phegly4 residue of the crosslinked heptapep- H125A (50 nM), or GtfB-D332A (3 M), were used in the reaction
tide aglycone. Other GTFs subsequently decorate either mixture, and no MgCl2 or CaCl2 was included in the incubation. From
the glucosyl moiety or other hydroxyl side chains of the a 325 l incubation, 75 l time points were taken at 0, 0.5, 1, and
2 hr and quenched with an equal volume of cold methanol. Thescaffold to diversify the carbohydrate moieties of this
reactions were analyzed by HPLC, followed by MALDI mass spec-class of antibiotics. The determination of the GtfB struc-
trometry. The HPLC column used in the analysis was a Vydac C18ture has defined a major subclass of the glycosyltrans-
small pore column (250  4.6 mm), run in a gradient of 0%–60%ferase superfamily. This will allow the exploration of
acetonitrile in water/0.1% TFA over 20 min at a flow rate of 1 ml/min.
mechanism and specificity for both NDP-sugar and agly- Km determinations for UDP-glucose were preformed as previously
cone selection, and it sets the stage for subsequent described for GtfB [30].
engineering of vancomycin group glycopeptides with
novel sugars and altered antibiotic properties. In partic- Crystallization, Data Collection, and Phasing
GtfB was crystallized by vapor diffusion from a hanging drop ofular, the two-domain structure of GtfB, with its single
equal parts 10 mg/ml protein solution and a reservoir solution ofinterdomain linker peptide, suggests strategies for con-
1.53 M MgSO4 and 2% PEG 400 in 100 mM MES buffer (pH 6.5).struction of chimeras between N- and C-terminal do-
The bipyramidal crystals (type 1) belong to tetragonal space group
mains that could selectively reprogram aglycone or P41212, with cell dimensions a  b  101.9 A˚, c  83.6 A˚ and one
NDP-sugar recognition, respectively, for the generation GtfB molecule per asymmetric unit. In the presence of up to 25 mM
UDP-glucose, isomorphous crystals (type 2) having identical cellof novel, hybrid glycopeptides with altered carbohydrate
dimensions (a  b  101.7 A˚, c  83.5 A˚) were grown using achains.
reservoir solution of 22% PEG 4000 and 0.23 M MgCl2 in 50 mM
MES buffer (pH 6.5).Experimental Procedures
For data collection, all crystals were transferred in a stepwise
manner to a solution matching the reservoir conditions but includingProtein Purification
30% glycerol as a cryo-protectant. The GtfB structure that wasThe gene encoding GtfB was cloned from Amycolatopsis orientalis
crystallized under type 1 conditions was solved by the multipleA82846 genomic DNA by PCR amplification using primers designed
isomorphous replacement (MIR) method. Four heavy-atom deriva-based on the published sequence of the chloroeremomycin biosyn-
tives were prepared by soaking native crystals in reservoir solutionsthetic cluster [6]. The forward primer introduced an NdeI restriction
containing one of the following compounds: 0.1 mM platinum dichl-site, and the reverse primer introduced a XhoI restriction site. The
orodiamine, 10 mM ethylmercurythiosalicylate, 10 mM UO2(NO3)2,digested PCR product was ligated into a pET22b expression vector
and 10 mM KAu(CN)2. An initial 2.8 A˚ native as well as heavy-atomthat adds a hexahistidine tag at the C terminus; ligations were trans-
derivative (2.8–3.0 A˚) data sets were measured at 160
C on aformed into E. coli DH5 cells, and the purified plasmid pET22b-
Siemens HI-STAR area detector with Osmic Max-Flux multilayergtfB-His6 was transformed into the E. coli expression strain
mirror optics. Data were processed and scaled with SAINT v5.00BL21(DE3). Liter cultures were grown at room temperature to an
(Bruker AXS). SOLVE v1.15 [31] was used to determine heavy-atomOD600 of 0.6, induced to 1 mM IPTG, and grown for an additional 4
positions and phases. A summary of data collection and phasinghr. Harvested cells were resuspended in 25 ml Buffer A (5 mM
statistics is shown in Table 2. Although the phasing power of someimidazole, 0.5 M NaCl, 25 mM Tris-Cl [pH 8]) and lysed by two
derivatives was low, the overall figure of merit was 0.60 to 3.2 A˚passages through a French pressure cell. After clarification by cen-
resolution. After density modification by solvent flattening using DMtrifugation at 95,000g, the lysate was loaded onto a charged 5 ml
[32] from the CCP4 suite of crystallographic software [33], initialHis•Bind column (Novagen) at a flow rate of 1 ml/min. The column
electron density maps were readily interpretable, and a model forwas washed with 50 ml Buffer A, followed by 30 ml of Buffer A with
GtfB was built using CHAIN interactive graphics [34]. Subsequently,30 mM imidazole. GtfB-His6 was eluted with a gradient of imidazole
data at 1.8 A˚ resolution were collected on beamline 19-ID at thein Buffer A (5–500 mM imidazole). Fractions were analyzed by SDS-
Advanced Photon Source at Argonne National Laboratory, pro-PAGE, pooled, and dialyzed twice against 3 liters of buffer consisting
cessed with HKL2000, and scaled using SCALEPACK [35]. For crys-of 50 mM Tris-Cl (pH 8) and 2 mM dithiothreitol (DTT). Protein con-
tals grown under type 2 conditions, data at 2.3 A˚ resolution werecentration was determined from the calculated extinction coefficient
collected on a Rigaku R-Axis IV image plate detector with Osmicof 37,560 M1 at 280 nm.
Max-Flux multilayer mirror optics. Data were processed and scaled
using HKL version 1.9.1 software [35].Construction and Analysis of Site-Directed Mutants
The mutants GtfB-D13A, GtfB-H125A, and GtfB-D332A were con-
structed using the splicing by overlap extension (SOE) method [28]. Structure Refinement
The type 1 GtfB structure was refined with CNSsolve v0.9a [36] usingFor each mutation, plasmid pET22b-gtfB served as a template for
the first round of PCR amplification. The 5 SOE fragments were simulated annealing in early stages, followed by simple positional
refinement. In later stages, individual B factors were refined, andamplified using the forward primer 5pET (CCATACCCACGCC
GAAACAAGC) and the reverse primer gtfB-D13A-5rev (CGGTTCGG solvent was added to the model. The current GtfB model includes
382 amino acids, with three disordered regions of the main chain.TAGCTCCGCGCGATCCAC) or gtfB-H125A-5rev (CTCGGACAGG
Structure
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Six residues and the His tag at the C terminus are also unobserved. 8. Mackay, J.P., Gerhard, U., Beauregard, D.A., Westwell, M.S.,
Searle, M.S., and Williams, D.H. (1994). Glycopeptide antibioticIn addition, 293 water molecules, one sulfate, and two Mg2 ions
have been added. The refined model yields the R factor 21.1% activity and the possible role of dimerization: a model for biologi-
cal signaling. J. Am. Chem. Soc. 116, 4581–4590.(37,146 reflections), with the Rfree of 23.1% for a test set of 2,867
reflections excluded from refinement calculations. The protein 9. Cooper, M.A., and Williams, D.H. (1999). Binding of glycopeptide
antibiotics to a model of a vancomycin-resistant bacterium.model conforms well to ideal geometry, as determined by PRO-
CHECK [37]. Chem. Biol. 6, 891–899.
10. Lambalot, R.H., Cane, D.E., Aparicio, J.J., and Katz, L. (1995).The refined protein coordinates of the type 1 structure were used
as a starting model for the isomorphous type 2 structure. An initial Overproduction and characterization of the erythromycin C-12
hydroxylase, EryK. Biochemistry 34, 1858–1866.R factor of 31.5% was reduced to 27.2% by one cycle of simulated
annealing. Structure refinement was continued using positional and 11. Gaisser, S., Bohm, G.A., Cortes, J., and Leadlay, P.F. (1997).
Analysis of seven genes from the eryAI-eryK region of the eryth-individual B factor refinement, as well as the addition of water mole-
cules, to yield a final R factor of 20.9% (18,161 reflections), with the romycin biosynthetic gene cluster in Saccharopolyspora
erythraea. Mol. Gen. Genet. 256, 239–251.Rfree of 24.1% (931 reflections). The refined type 2 protein structure
12. Gaisser, S., et al., and Leadlay, P.F. (1998). Analysis of eryBI,is virtually identical to the type 1 model. No electron density was
eryBIII and eryBVII from the erythromycin biosynthetic geneobserved for bound UDP-glucose substrate. Moreover, the GtfB
cluster in Saccharopolyspora erythraea. Mol. Gen. Genet. 258,structure showed greater conformational disorder than was ob-
78–88.served from type 1 crystals grown in high salt conditions, with four
13. Quiros, L.M., Carbajo, R.J., Brana, A.F., and Salas, J.A. (2000).breaks in the protein main chain and six additional unobserved
Glycosylation of macrolide antibiotics; purification and kineticamino acids. The type 2 structure includes two Mg2 cations and 163
studies of a macrolide glycosyltransferase from Streptomycesindependently determined water molecules, most of which coincide
antibioticus. J. Biol. Chem. 275, 11713–11720.with positions identified in the type 1 structure. Subsequently, a 1.9
14. Vrielink, A., Ruger, W., Driessen, H.P.C., and Freemont, P.S.A˚ resolution data set was collected on beamline X-25 at the National
(1994). Crystal structure of the DNA modifying enzyme beta-Synchrotron Light Source, Brookhaven National Laboratory. The
glucosyltransferase in the presence and absence of the sub-data were processed and scaled using HKL version 1.96.6 software
strate uridine diphosphoglucose. EMBO J. 13, 3413–3422.[35]. However, refinement against the higher resolution data (R factor
15. Ha, S., Walker, D., Shi, Y., and Walker, S. (2000). The 1.9 A˚of 24.3%, Rfree of 26.8%) yielded identical results, with no indication
crystal structure of E. coli MurG, a membrane-associated glyco-of bound UDP-glucose, and was not pursued further. Refinement
syltransferase involved in peptidoglycan biosynthesis. Proteinresults for type 1 and type 2 structures are summarized in Table 3.
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